Application of glucosamine-derived oligosaccharide in preparation of medicine for preventing and treating lung diseases

Through the preparation and application of glucosamine-derived oligosaccharides, the existing drugs for treating interstitial pneumonia and pulmonary fibrosis have been solved, and effective prevention and treatment of lung diseases, especially pulmonary fibrosis has been achieved. Improved, with high safety and minor side effects.

CN118903185AInactive Publication Date: 2024-11-08ANHUI MEDICAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410989324.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing drugs for the treatment of interstitial pneumonia and pulmonary fibrosis have great side effects and lack effective new drug solutions. Finding new treatment methods is an urgent task.

Method used

Glucosamine-derived oligosaccharides are prepared by chitosan enzyme decomposition to obtain glucosamine-derived oligosaccharides with a relative molecular weight of 200-5000 Da, which are used to prepare drugs for preventing and treating lung diseases, including pneumonia and pulmonary fibrosis. The pharmaceutical composition is oral, intravenous, intramuscular, etc., and is used to prevent and treat lung diseases.

Benefits of technology

Glucosamine-derived oligosaccharides can effectively prevent and treat lung diseases, especially for diseases that may cause lung fibrosis. They have high safety and small side effects, can relieve lung fibrosis and lung inflammation, and improve lung tissue morphology changes. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903185A_ABST
    Figure CN118903185A_ABST
Patent Text Reader

Abstract

The invention discloses application of glucosamine-derived oligosaccharide in preparation of a medicine for preventing and treating lung diseases, and belongs to the technical field of biology. The glucosamine-derived oligosaccharide is prepared from the chitosan derivative through enzymolysis, and the glucosamine-derived oligosaccharide can effectively prevent and treat lung diseases, especially has a remarkable curative effect on lung tissue morphological change, interstitial pneumonia and pulmonary fibrosis caused by environmental toxins, and is high in safety and small in side effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to the application of glucosamine-derived oligosaccharides in the preparation of medicines for preventing and treating lung diseases. Background Art

[0002] Interstitial pneumonia is a disease of interstitial lung inflammation and fibrosis caused by various reasons. It mainly invades the pulmonary interstitium and alveolar cavity, including alveolar epithelial cells, capillary endothelial cells, basement membrane, blood vessels and lymph nodes, and the tissue around the ducts, eventually leading to pulmonary interstitial fibrosis and loss of alveolar capillary function.

[0003] The current treatment options for interstitial pneumonia and pulmonary fibrosis mainly include staying away from inducing factors, anti-inflammatory treatment, anti-fibrosis treatment, and prevention and treatment of hypoxemia. Clinical drugs are mainly pirfenidone and nintedanib, which have great side effects. Finding new drugs to treat interstitial pneumonia and pulmonary fibrosis is a difficult and important task that needs to be solved urgently.

[0004] Glucosamine-derived oligosaccharides are small molecule bioactive substances formed by the hydrolysis of chitosan. Their biological activities include antioxidant, antibacterial, improving plant disease resistance, and promoting plant growth. They are widely used in medicine, health products, agriculture, etc. Existing studies have not found that they are related to lung-related diseases. Summary of the invention

[0005] In view of the technical problems existing in the prior art, the present invention proposes a glucosamine-derived oligosaccharide for preventing and treating lung diseases, which includes a compound with the following structure:

[0006]

[0007] Wherein, R1 is a hydrogen atom, an acetyl group, a carboxymethyl group or a hydroxypropyl group; R2 is a hydrogen atom, a carboxymethyl group or a hydroxypropyl group; and n is an integer of 2 to 20.

[0008] In some embodiments, wherein n is 3-6.

[0009] In some embodiments, the glucosamine-derived oligosaccharide is chitotriose.

[0010] In some embodiments, the relative molecular weight of the glucosamine-derived oligosaccharide is 200-5000 Da; preferably, the relative molecular weight is 200-3000 Da; more preferably, the relative molecular weight is 200-1000 Da; further preferably, the relative molecular weight is 400-600 Da.

[0011] In some embodiments, the lung disease is caused by drug ingestion, viral infection, bacterial infection, mycoplasma infection, lung cell gene mutation, genetic susceptibility, dust, hair, haze, radiotherapy, high-concentration oxygen therapy, smoking, and gastroesophageal reflux.

[0012] In some embodiments, the pulmonary disease comprises at least one of pneumonia and pulmonary fibrosis.

[0013] In some embodiments, the lung disease is at least one of idiopathic interstitial pneumonia, common interstitial pneumonia, idiopathic nonspecific interstitial pneumonia, idiopathic pulmonary fibrosis, secondary pulmonary fibrosis, and hereditary pulmonary fibrosis.

[0014] In some embodiments, the pulmonary disease is at least one of bleomycin-induced changes in lung tissue morphology, interstitial inflammation, and pulmonary fibrosis.

[0015] In some embodiments, the drug is a solution, a suspension, a tablet, a capsule, a granule, an injection or an infusion.

[0016] In some embodiments, the method for preparing the glucosamine-derived oligosaccharides comprises the following steps: taking chitosan, dispersing it in pure water, and adjusting the pH to 5-6; adding chitosanase, performing enzymolysis at 30°C-50°C, and inactivating the chitosanase at high temperature after sufficient enzymolysis; centrifuging the precipitate, collecting the supernatant, and performing vacuum freeze-drying to obtain a crude product; and separating and purifying the crude product to obtain a glucosamine-derived oligosaccharide product.

[0017] In some embodiments, the lung disease is a disease that may cause pulmonary fibrosis.

[0018] In some embodiments, the disease that may cause pulmonary fibrosis is interstitial pneumonia.

[0019] The present application relates to a pharmaceutical composition for preventing and treating lung diseases in a subject, comprising a preventive and therapeutic effective amount of a compound of the structure shown in Formula I and an environmental toxin that can cause lung diseases:

[0020]

[0021] Wherein, R1 is a hydrogen atom or an acetyl group or a carboxymethyl group or a hydroxypropyl group; R2 is -H or a carboxymethyl group or a hydroxypropyl group; and n is an integer of 2-20.

[0022] In some embodiments, the active substance that can cause lung disease is bleomycin.

[0023] In some embodiments, the pharmaceutical composition is administered orally, intravenously, intramuscularly, rectally, intradermally or subcutaneously.

[0024] In some embodiments, the drug composition is administered once a day during the treatment cycle, 200 mg / kg each time.

[0025] The present application relates to the use of glucosamine-derived oligosaccharides in the preparation of drugs for preventing and treating lung diseases, wherein the lung diseases include at least one of interstitial pneumonia and pulmonary fibrosis.

[0026] In some embodiments, the pulmonary disease comprises at least one of bleomycin-induced changes in lung tissue morphology, interstitial pneumonia, and pulmonary fibrosis.

[0027] The present application provides a drug for preventing and / or treating lung diseases, which can effectively prevent and / or treat lung diseases, especially lung diseases that may cause pulmonary fibrosis, with high safety and few side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The results are as follows: the effects of different concentrations of glucosamine-derived oligosaccharides on the activity of normal human lung epithelial BEAS-2B cells according to one embodiment of the present invention.

[0029] Figure 2 is a schematic diagram of a drug administration scheme according to one embodiment of the present invention.

[0030] Figure 3 is a diagram of lung tissue morphology according to an embodiment of the present invention.

[0031] Figure 4 This is the result of hematoxylin and eosin staining of lung tissue pathological sections according to one embodiment of the present invention.

[0032] Figure 5 This is the Masson's trichrome staining result of lung tissue pathological sections according to one embodiment of the present invention. DETAILED DESCRIPTION

[0033] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0034] According to the different causes, interstitial pneumonia is mainly divided into interstitial pneumonia with known causes and idiopathic interstitial pneumonia. Interstitial pneumonia with known causes includes allergic pneumonia, drug-induced interstitial pneumonia, connective tissue disease-related interstitial pneumonia, pneumoconiosis, etc. Idiopathic interstitial pneumonia includes common interstitial pneumonia, nonspecific interstitial pneumonia, bronchiolitis obliterans with organizing pneumonia, respiratory bronchiolitis with interstitial lung disease, desquamative interstitial pneumonia and acute interstitial pneumonia.

[0035] The main clinical manifestations of interstitial pneumonia are dyspnea and cough. Some patients may have systemic symptoms such as fever and fatigue. The progression of interstitial pneumonia can cause pulmonary fibrosis. In the early stages of lung tissue damage, inflammatory cells are recruited, leading to the release of chemokines and proinflammatory cytokines, followed by a large number of inflammatory cells, tissue remodeling, and accumulation of collagen fibers in the lungs. Subsequently, healthy tissue is replaced by altered extracellular matrix, and the alveolar structure is destroyed, resulting in decreased lung compliance and lung function, interrupted gas exchange, and ultimately respiratory failure and death.

[0036] The present application relates to the use of glucosamine-derived oligosaccharides in the preparation of drugs for preventing and treating lung diseases. The present application has found that glucosamine-derived oligosaccharides can effectively alleviate pulmonary fibrosis and lung inflammation.

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention. Some of the terms involved in this application have the following meanings:

[0038] The term "and / or" is intended to include any and all combinations of one or more of the associated listed items.

[0039] In some embodiments, the glucosamine-derived oligosaccharide is an oligosaccharide derivative of acetylglucosamine or glucosamine. Further, in some embodiments, the glucosamine-derived oligosaccharide is a trisaccharide composed of glucosamine.

[0040] The term "diseases that may cause pulmonary fibrosis" may refer to lung diseases caused by bacteria, viruses, mycoplasma infections, etc. that may develop into pulmonary fibrosis; it may also refer to lung lesions caused by mutations in lung cells themselves that may develop into pulmonary fibrosis; it may also refer to patients receiving drugs that have toxic side effects on the lungs due to prevention or treatment of other diseases, which may cause pulmonary fibrosis, etc. The diseases that may cause pulmonary fibrosis are not limited to diseases that originate in the lungs, but may also be other diseases that develop, metastasize to the lungs, diseases that act on the lungs through drug side effects, etc.

[0041] The term "pneumonia" refers to both common lung inflammation and inflammatory diseases that can cause pulmonary fibrosis after disease development. Pneumonia can be pneumonia caused by infection with bacteria, viruses, mycoplasmas and other foreign bodies, or pneumonia formed after the occurrence, development and metastasis of other diseases, or pneumonia caused by cell mutations. In some embodiments, the pneumonia is interstitial pneumonia. Furthermore, in some embodiments, interstitial pneumonia is idiopathic interstitial pneumonia, common interstitial pneumonia or idiopathic nonspecific interstitial pneumonia.

[0042] The term "bleomycin" (BLM), also known as bleomycin, is a cytotoxic glycoprotein isolated from Streptomyces verticillium. It is clinically used as a broad-spectrum antitumor / antibacterial drug to treat a variety of cancers. BLM causes DNA chain breaks in tumor cells and causes cell apoptosis, but due to insufficient BLM hydrolase in the lungs, long-term or excessive use of BLM can cause pulmonary fibrosis, so it is often used to construct animal models of pulmonary fibrosis. BLM has a wide range of applications and can induce pulmonary fibrosis in rodents such as mice, rats or rabbits, dogs and various primates. BLM has a variety of administration routes, including intraperitoneal injection, tail vein injection, tracheal administration, nasal instillation and nebulization inhalation, and single and repeated administration can well induce animal pulmonary fibrosis. At present, the most commonly used route of administration is tracheal administration. The animal model induced by tracheal administration can better simulate the pathological changes of human pulmonary fibrosis, and has the advantages of short modeling time and small dosage.

[0043] The following is a detailed description in conjunction with specific embodiments. Unless otherwise specified in the following embodiments, other components except inevitable impurities are not included.

[0044] Unless otherwise specified, the reagents and instruments used in the examples are routinely selected in the art.

[0045] The experimental methods without specific conditions in the examples are carried out according to conventional conditions, such as the conditions described in the literature, books or methods recommended by the manufacturer.

[0046] In the present invention, n represents the degree of polymerization; for example, n=2-4, which means the degree of polymerization is 2-4.

[0047] In the present invention, COS represents glucosamine oligosaccharide.

[0048] In the present invention, CMCOS means carboxymethylglucosamine oligosaccharide.

[0049] In the present invention, HPCOS means hydroxypropyl glucosamine oligosaccharide.

[0050] In the present invention, JACOS represents a quaternary ammonium salt of glucosamine oligosaccharide.

[0051] In the present invention, COS-HCl means glucosamine oligosaccharide hydrochloride.

[0052] In the present invention, DMEM culture medium is a culture medium containing various amino acids and glucose, purchased from Merck.

[0053] In the present invention, gradient enzymatic hydrolysis refers to multiple step-by-step enzymatic hydrolysis, such as first-degree enzymatic hydrolysis, which means one enzymatic hydrolysis reaction is performed; second-degree enzymatic hydrolysis, which means using the product obtained after one enzymatic hydrolysis reaction as a reaction substrate, and performing another enzymatic hydrolysis reaction under optimized conditions; and so on.

[0054] Example 1: Preparation method of glucosamine trisaccharide

[0055] Take 40g of chitosan, disperse it in 400mL of water, adjust the pH to 5.5 with HCl aqueous solution, add 0.1g of chitosanase, stir and react in a constant temperature water bath at 40℃ for 48h, then react in a water bath at 65℃ for 1h to inactivate chitosanase. Centrifuge at 4000rpm to collect the supernatant and separate the precipitate to obtain the reaction product, place the reactant at -80℃ overnight, then perform vacuum freeze drying, and obtain glucosamine trisaccharide after separation and purification.

[0056] Example 2: Preparation of different types of glucosamine-derived oligosaccharides

[0057] According to the method in Example 1, other conditions remain unchanged, and the type of enzyme, enzyme reaction temperature, enzyme reaction pH value, enzyme reaction gradient, separation and purification conditions in the enzymatic hydrolysis conditions are changed to prepare different types of glucosamine-derived oligosaccharides. The results are shown in Table 1.

[0058] Table 1

[0059] Reactants Enzymes temperature pH Enzyme gradient product Carboxymethyl chitosan Chitosanase 40℃ 5 1 Carboxymethyl Glucosamine Oligosaccharide Hydroxypropyl Chitosan Chitosanase 50℃ 4 1 Hydroxypropyl Glucosamine Oligosaccharide Chitosan quaternary ammonium salt Chitosanase 45℃ 6 1 Glucosamine oligosaccharide quaternary ammonium salt Chitosan hydrochloride Chitosanase 60℃ 5 1 Glucosamine oligosaccharide hydrochloride Chitosan Chitosanase 40℃ 5.5 3 Glucosamine oligosaccharide n is 2-4 Chitosan Chitosanase 40℃ 5.5 2 Glucosamine oligosaccharide n is 5-7 Chitosan Chitosanase 40℃ 5.5 1 Glucosamine oligosaccharide n is 8-10

[0060] Example 3: Biosafety Assay

[0061] In order to evaluate the safety of glucosamine-derived oligosaccharides, normal human lung epithelial cells BEAS-2B cells were treated with different concentrations of glucosamine-derived oligosaccharides ranging from 0 to 3000 μg / mL for 24 h.

[0062] Specific operations include:

[0063] 1. BEAS-2B cells were cultured with DMEM complete medium at 37°C and 5% CO2. During normal culture, fresh complete medium was replaced every 2 days. When the cells reached 90% confluence, they were passaged at a ratio of 1:3.

[0064] 2. BEAS-2B cells were seeded in a 96-well plate. On the second day, glucosamine-derived oligosaccharides were added to give final concentrations of 0, 50, 100, 200, 500, 1000, 1500, 2000, 2500, and 3000 μg / ml, and the cells were treated for 24 h.

[0065] 3. In the dark, add 20 μl of MTT solution (concentration of 5.0 mg / ml) to each well and continue incubating in the cell culture incubator for 4 h.

[0066] 4. Discard the culture medium, add 150 μl DMSO solution to each well, and shake on a shaker for 10 minutes.

[0067] 5. Measure the absorbance at 492 nm.

[0068] The results are as follows Figure 1 As shown. Figure 1 It can be seen that glucosamine-derived oligosaccharides have no significant effect on the viability of BEAS-2B cells. Therefore, glucosamine-derived oligosaccharides have high biosafety.

[0069] Example 4: Glucosamine-derived oligosaccharides improve bleomycin-induced lung tissue morphological damage

[0070] We used BLM to construct mouse models of interstitial pneumonia and pulmonary fibrosis. Figure 2 shown.

[0071] Specifically, ICR male mice were divided into 14 groups, including 2 control groups, 2 model groups, 5 prevention groups (COS, CMCOS, HPCOS, JACOS and COS-HCl) and 5 treatment groups (COS, CMCOS, HPCOS, JACOS and COS-HCl), with 6 mice in each group.

[0072] The model group, prevention group and treatment group were given BLM on day 0 (BLM was instilled into the mouse trachea at a dose of 5 mg / kg), and the control group was given an equal amount of normal saline as a negative control.

[0073] One day after BLM was instilled into the trachea, mice in the prevention group were given COS, CMCOS, HPCOS, JACOS and COS-HCL by gavage, once a day, 200 mg / kg each time. The mice in the control group and the model group were given an equal amount of distilled water, and the mice in each group were killed on the 28th day for observation of lung tissue morphology. The results are shown in Figure 3 shown.

[0074] Fourteen days after tracheal instillation of BLM, COS, CMCOS, HPCOS, JACOS and COS-HCL were administered orally to the mice in the treatment group once a day at 200 mg / kg each time. The mice in the control group and the model group were given an equal amount of distilled water, and the mice in each group were killed on the 28th day for observation of lung tissue morphology. The results are shown in Figure 3 shown.

[0075] The results are as follows Figure 3 As shown. Figure 3 It can be seen that the lung surface of the mice in the control group is bright red, smooth and elastic. The lung surface of the mice in the model group is more uneven, less elastic, dark red, with large ecchymoses and gray-white nodules. The lung surface of the mice in the prevention group is smoother, slightly red in some parts, with good elasticity, a small number of bleeding spots, and the nodules have improved. Bleeding spots can be seen in the lungs of the mice in the treatment group, but the overall situation is better than that of the model group. This shows that glucosamine-derived oligosaccharides can improve the changes in lung tissue morphology caused by bleomycin to a certain extent.

[0076] Example 5: Treatment of interstitial inflammation and pulmonary fibrosis induced by bleomycin with glucosamine-derived oligosaccharides

[0077] We used BLM to construct mouse models of interstitial pneumonia and pulmonary fibrosis. Figure 2 shown.

[0078] Specifically, ICR male mice were divided into 12 groups, including 3 control groups, 3 model groups, 3 prevention groups and 3 treatment groups, with 6 mice in each group.

[0079] Among them, the model group, prevention group and treatment group were given 5 mg / kg BLM by tracheal instillation on day 0, and the control group was given an equal amount of normal saline as a negative control.

[0080] One day after tracheal instillation of BLM, mice in the prevention group were gavaged with COS of different polymerization degrees (n=2-4, n=5-7, n=8-10), once a day, 200 mg / kg each time. 14 days after tracheal instillation of BLM, mice in the treatment group were gavaged with COS of different polymerization degrees (n=2-4, n=5-7, n=8-10), once a day, 200 mg / kg each time. The control group and model group mice were given an equal amount of distilled water, and the mice in each group were killed on the 28th day for lung tissue morphology observation. The results are shown in Figure 2. Figure 4 and Figure 5 shown.

[0081] like Figure 4 The figure shows the hematoxylin and eosin staining results of lung tissue sections of mice sacrificed on the 28th day according to one embodiment of the present application. Figure 4The results showed that the lung structure in the model group was destroyed, the alveoli disappeared, and a large number of inflammatory cells infiltrated. However, after COS treatment, the alveolar structure was significantly improved, and the inflammatory cell infiltration was significantly better than that in the model group. After COS treatment on the 15th day of BLM model construction, although the alveolar structure was slightly destroyed and the alveolar wall was thickened, the inflammatory cell infiltration was significantly better than that in the model group.

[0082] Figure 5 This is the result of Masson's trichrome staining of lung tissue sections. Figure 5 The results showed that the alveolar wall of the model group was thickened, the lung structure was severely damaged, and a large amount of blue collagen fibers were deposited in the interstitial space of the lung, indicating the presence of pulmonary fibrosis. After COS prevention and treatment, the symptoms of pulmonary fibrosis were significantly improved.

[0083] The above-described embodiments only express several implementation methods of the present invention, which are convenient for understanding the technical solutions of the present invention in detail, but they cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided by the present invention are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the contents of the attached claims, and the description and drawings can be used to interpret the contents of the claims.

Claims

1. Use of glucosamine-derived oligosaccharides in the preparation of drugs for preventing and treating lung diseases, characterized in that: The glucosamine-derived oligosaccharide has the following structure: Wherein, R1 is a hydrogen atom, an acetyl group, a carboxymethyl group or a hydroxypropyl group; R2 is a hydrogen atom, a carboxymethyl group or a hydroxypropyl group; and n is an integer of 2-20.

2. The use according to claim 1, characterized in that in, n is 3-6.

3. The use according to claim 1, characterized in that: The glucosamine-derived oligosaccharide is glucosamine trisaccharide.

4. The use according to claim 1, characterized in that: The relative molecular weight of the glucosamine-derived oligosaccharide is 200-5000Da; preferably, the relative molecular weight is 200-3000Da; more preferably, the relative molecular weight is 200-1000Da; further preferably, the relative molecular weight is 400-600Da.

5. The use according to claim 1, characterized in that: The lung disease is caused by drug ingestion, viral infection, bacterial infection, mycoplasma infection, lung cell gene mutation, genetic susceptibility, dust, hair, haze, radiotherapy, high-concentration oxygen therapy, smoking or gastroesophageal reflux.

6. The use according to claim 1, characterized in that: The lung disease includes at least one of pneumonia and pulmonary fibrosis.

7. The use according to claim 4, characterized in that: The lung disease is at least one of idiopathic interstitial pneumonia, common interstitial pneumonia, idiopathic nonspecific interstitial pneumonia, idiopathic pulmonary fibrosis, secondary pulmonary fibrosis, and hereditary pulmonary fibrosis.

8. The use according to claim 1, characterized in that: The lung disease is at least one of bleomycin-induced changes in lung tissue morphology, interstitial pneumonia and pulmonary fibrosis.

9. The use according to claim 1, characterized in that: The medicine is a solution, suspension, tablet, capsule, granule, injection or infusion.

10. A method for preparing the glucosamine-derived oligosaccharide according to claim 1, characterized in that: The method comprises the following steps: taking a chitosan derivative, dispersing it in pure water, adjusting the pH to 5-6, adding chitosanase, performing enzymolysis at 30-50°C, inactivating the chitosanase at high temperature after sufficient enzymolysis, centrifuging and separating the precipitate, collecting the supernatant, performing vacuum freeze drying to obtain a crude product, and separating and purifying the crude product to obtain a glucosamine-derived oligosaccharide product.

Citation Information

Patent Citations

  • Application of glucosamine in preparation of drug for preventing and treating ionizing radiation induced pulmonary injury

    CN107823211A

  • Method for preparing chitooligosaccharide with snailase and application thereof

    CN109136307A